Global GLP-1 market on track for $133.92b by 2034

Asia Pacific is projected to post the fastest regional growth.

The global GLP-1 drug market is projected to grow to $133.92b by 2034, as therapeutic use expands beyond diabetes into obesity and cardiovascular disease.

According to Polaris Market Research, long-acting GLP-1 agonists dominated the market in 2025, driven by less frequent dosing and sustained therapeutic effect.

Oral formulations are set to grow fastest through 2034 as patients seek non-injectable alternatives, whilst biologics are expected to post the strongest gains amongst molecule types due to their extended half-life and precise targeting.

By indication, obesity was the largest segment in 2025, supported by expanding regulatory approvals and growing clinical acceptance of GLP-1 drugs for weight management.

The underlying disease burden remains substantial, as the World Health Organisation (WHO) estimated roughly 830 million people had diabetes worldwide in 2022, with more than 95% classified as type 2.

Separately, the WHO reported 2.5 billion adults were overweight globally in 2022, including 890 million living with obesity.

Asia Pacific is projected to post the fastest regional growth through 2034, driven by rising rates of lifestyle-related disease and improving healthcare access.

India alone recorded 101 million diabetes cases in a 2023 study by the Indian Council of Medical Research.

China's market is also expanding, supported by government investment in chronic disease management and broader access to newer treatments.

High treatment costs and affordability remain the market's primary constraint, the report notes, even as the ageing population, projected by the UN to rise from 761 million people aged 65 and over in 2021 to 1.6 billion by 2050, adds further long-term demand for glycemic and cardiometabolic therapies.